Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Analyzers, Service), Application (Respiratory Diseases, HAIs, STDs, Cancer, Hepatitis), Technology (RT-PCR, INAAT), End User (Physician Office, Hospitals, ICUs) - Global Forecast to 2026
Instant Answers with GPT - Ask Now!
Ask real questions. Get complete answers !
Generating Response ...Updated on : April 18, 2023
The global point of care molecular diagnostics market in terms of revenue was estimated to be worth $2.8 billion in 2021 and is poised to reach $4.1 billion by 2026, growing at a CAGR of 8.2% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests.
To know about the assumptions considered for the study, Request for Free Sample Report
Point of Care Molecular Diagnostics Market Dynamics
Driver: Increasing prevalence of infectious diseases and cancer
The increasing prevalence of infectious diseases and cancer in developed and developing regions will positively influence the growth of the market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for molecular diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for point-of-care molecular diagnostics during the forecast period.
Opportunity: Growth opportunities in emerging countries
Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infectious diseases, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries.
Restraint: Unfavourable reimbursement scenario
Inadequate reimbursements are a major factor restraining the growth of the market. A major challenge that most diagnostic companies face in commercializing their tests is getting Medicare and private health insurers to pay for them. In the US, Medicare revised its reimbursement mechanism for some IVD tests, including point-of-care molecular tests, in 2018. Some of these tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions. Centers for Medicare & Medicaid Services (CMS) reduced the Medicare reimbursement rate for COVID-19 tests based on high throughput technology to USD 75 unless labs can process results in under two days. Medicare does not currently provide genetic testing coverage in individuals without a personal history of cancer (Source: American Society of Clinical Oncology).
Assays & kits segment accounted for the largest share of the point of care molecular diagnostics market, by product & service
Based on product, the market is segmented into instruments & analyzers, and software & services. The assays & kits segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.
RT-PCR segment accounted for the largest share in the point of care molecular diagnostics market, by technology
The market is segmented into RT-PCR, INAAT and other technologies based on technology. The RT-PCR segment accounted for the largest share. This can be attributed to the growing use of RT-PCR in proteomics, genomics, and COVID-19 testing as well as the access to portable, easy-to-use devices are the major factors driving the growth of this market segment.
North America is the largest region of point of care molecular diagnostics market
The global market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America accounted for the largest share of the global market. The North American market's growth can be attributed to the highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments.
To know about the assumptions considered for the study, download the pdf brochure
Some key players in the point of care molecular diagnostics market are
- Abbott Laboratories (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- bioMérieux SA (France)
- Danaher Corporation (US)
- Quidel Corporation (US)
- QIAGEN N.V. (Netherlands)
- Co-Diagnostics, Inc. (US)
- Biocartis NV (Belgium)
- Meridian Bioscience, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- Lucira Health, Inc. (US)
- Cue Health (US)
- OpGen, Inc. (US)
- Binx Health, Inc. (US)
- Molbio Diagnostics Pct. Ltd. (India)
- Genomadix (Canada)
- Visby Medical, Inc. (US)
- QuikPath PTE Ltd. (Singapore)
- MD-Bio (US)
- QuantuMDx Group Ltd. (UK)
- Aidian Oy (Finland)
- GeneSTAT Molecular Diagnostics, LLC (US).
Point of Care Molecular Diagnostics Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$2.8 billion |
|
Estimated Value by 2026 |
$4.1 billion |
|
Growth Rate |
poised to grow at a CAGR of 8.2% |
|
Largest Share Segments |
Assays and Kits & RT-PCR |
|
Market Report Segmentation |
By Product & Service, Application, Technology, End User & Region |
|
Growth Driver |
Increasing prevalence of infectious diseases and cancer |
|
Growth Opportunity |
Growth opportunities in emerging countries |
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the point of care molecular diagnostics market into the following segments and sub-segments:
By Product & Service
- Assays & kits
- Instruments & Analyzers
- Software & Services
By Technology
- RT-PCR
- INAAT
- Other technologies
By Applic?ation
- Respiratory Diseases
- Sexually Transmitted Diseases
- Hospital-acquired Infections
- Cancer
- Hepatitis
- Gastrointestinal Disorders
- Other Applications
By End User
- Physicians’ Offices
- Hospitals & ICUs
- Research Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- UK
- Germany
- France
- Italy
- Rest of Europe (RoE)
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Rest of the World (RoW)
Recent Developments
- In October 2020, bioMérieux SA partnered with Africa Medical Supplies Platform (AMSP) to supply high-quality COVID-19 diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.
- In March 2020, Abbott Laboratories launched the ID NOW PoC testing system.
- In October 2018, QIAGEN signed an agreement with STAT-Dx to add QIAstat-Dx, a next-generation PCR-based multiplex syndromic testing solution, to QIAGEN’s portfolio
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global point of care molecular diagnostics market?
The global point of care molecular diagnostics market boasts a total revenue value of $4.1 billion by 2026.
What is the estimated growth rate (CAGR) of the global point of care molecular diagnostics market?
The global market for point of care molecular diagnostics has an estimated compound annual growth rate (CAGR) of 8.2% and a revenue size in the region of $2.8 billion in 2021.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 34)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Market estimation from the parent market
FIGURE 6 BOTTOM-UP APPROACH: MARKET ESTIMATION FROM THE PARENT MARKET
2.3.1.3 Approach 3: Presentations of companies and primary interviews
2.3.1.4 Growth forecast
2.3.1.5 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 COVID-19 HEALTH ASSESSMENT
2.10 COVID-19 ECONOMIC ASSESSMENT
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 11 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE MARKET
3 EXECUTIVE SUMMARY (Page No. - 53)
FIGURE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 58)
4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 17 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 18 ASSAYS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 19 RT-PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 20 RESPIRATORY DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.5 MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 21 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
5.2.1.3 Increasing awareness on the early detection of infectious diseases
5.2.1.4 Increasing use of POC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High capital investments and low cost-benefit ratio
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in POINT OF CARE MOLECULAR DIAGNOSTICS testing
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase the product launch cycle
5.2.4.2 Introduction of alternative technologies
5.3 IMPACT OF COVID-19 ON THE MARKET
5.4 PRICING ANALYSIS
TABLE 1 PRICES OF POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS (2021)
5.5 PATENT ANALYSIS
5.6 TRADE ANALYSIS
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
5.7 VALUE CHAIN ANALYSIS
FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 25 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS
FIGURE 26 MARKET: ECOSYSTEM ANALYSIS
5.9.1 ROLE IN THE ECOSYSTEM
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT FROM NEW ENTRANTS
5.10.2 THREAT FROM SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
5.11 PESTLE ANALYSIS
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 CANADA
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 Japan
5.12.3.2 India
5.12.3.3 China
5.12.4 LATIN AMERICA
5.12.4.1 Brazil
5.12.4.2 Mexico
5.12.5 MIDDLE EAST
5.12.6 AFRICA
5.13 TECHNOLOGY ANALYSIS
5.14 DISRUPTIVE TECHNOLOGIES IN THE MARKET
5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR THE POC MOLECULAR DIAGNOSTICS MARKET
FIGURE 27 REVENUE SHIFT FOR THE MARKET
6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 81)
6.1 INTRODUCTION
TABLE 5 MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 6 MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
6.2 ASSAYS & KITS
6.2.1 RECURRENT PURCHASE OF ASSAYS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 7 MARKET FOR ASSAYS & KITS, BY REGION, 2018–2020 (USD MILLION)
TABLE 8 MARKET FOR ASSAYS & KITS, BY REGION, 2021–2026 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 9 MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2018–2020 (USD MILLION)
TABLE 10 MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2018–2020 (USD MILLION)
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2026 (USD MILLION)
7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 87)
7.1 INTRODUCTION
TABLE 13 MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 14 MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
7.2 RT-PCR
7.2.1 GROWING USE OF RT-PCR IN COVID-19 TESTING IS A MAJOR DRIVER FOR THIS SEGMENT
TABLE 15 MARKET FOR RT-PCR, BY REGION, 2018–2020 (USD MILLION)
TABLE 16 MARKET FOR RT-PCR, BY REGION, 2021–2026 (USD MILLION)
7.3 INAAT
7.3.1 COST BENEFITS OF INAAT ARE A KEY FACTOR DRIVING MARKET GROWTH
TABLE 17 MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION)
TABLE 18 MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION)
7.4 OTHER TECHNOLOGIES
TABLE 19 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION)
TABLE 20 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)
8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 93)
8.1 INTRODUCTION
TABLE 21 MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 22 MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
8.2 RESPIRATORY DISEASES
8.2.1 GROWING PREVALENCE OF COVID-19 TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 23 MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018–2020 (USD MILLION)
TABLE 24 MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2026 (USD MILLION)
8.3 SEXUALLY TRANSMITTED DISEASES
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE DETECTION OF STDS PLAY A MAJOR ROLE IN DRIVING THE GROWTH OF THIS MARKET
TABLE 25 MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018–2020 (USD MILLION)
TABLE 26 MARKET SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2026 (USD MILLION)
8.4 HOSPITAL-ACQUIRED INFECTIONS
8.4.1 RISING BURDEN OF MRSA WILL DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS
TABLE 27 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018–2020 (USD MILLION)
TABLE 28 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2026 (USD MILLION)
8.5 CANCER
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET GROWTH
TABLE 29 MARKET FOR CANCER, BY REGION, 2018–2020 (USD MILLION)
TABLE 30 MARKET FOR CANCER, BY REGION, 2021–2026 (USD MILLION)
8.6 HEPATITIS
8.6.1 INCREASE IN CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO DRIVE MARKET GROWTH
TABLE 31 MARKET FOR HEPATITIS, BY REGION, 2018–2020 (USD MILLION)
TABLE 32 MARKET FOR HEPATITIS, BY REGION, 2021–2026 (USD MILLION)
8.7 GASTROINTESTINAL DISORDERS
8.7.1 INCREASE CASES OF GASTROINTESTINAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 33 MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2018–2020 (USD MILLION)
TABLE 34 MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2026 (USD MILLION)
8.8 OTHER APPLICATIONS
TABLE 35 MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2020 (USD MILLION)
TABLE 36 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2026 (USD MILLION)
9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 105)
9.1 INTRODUCTION
TABLE 37 MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 38 MARKET, BY END USER, 2021–2026 (USD MILLION)
9.2 PHYSICIANS’ OFFICES
9.2.1 EARLY RESULTS OF POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH IN THIS MARKET
TABLE 39 MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2018–2020 (USD MILLION)
TABLE 40 MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2026 (USD MILLION)
9.3 HOSPITALS & ICUS
TABLE 41 MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2018–2020 (USD MILLION)
TABLE 42 MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2026 (USD MILLION)
TABLE 43 MARKET FOR HOSPITALS & ICUS, BY REGION, 2018–2020 (USD MILLION)
TABLE 44 MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2026 (USD MILLION)
9.3.1 SEPSIS
9.3.1.1 Growing need for quick diagnosis and treatment will drive growth in this market
TABLE 45 MARKET FOR SEPSIS, BY REGION, 2018–2020 (USD MILLION)
TABLE 46 MARKET FOR SEPSIS, BY REGION, 2021–2026 (USD MILLION)
9.3.2 GASTROENTERITIS
9.3.2.1 Increasing number of gastroenteritis cases in hospital emergency departments to propel growth in this market
TABLE 47 MARKET FOR GASTROENTERITIS, BY REGION, 2018–2020 (USD MILLION)
TABLE 48 MARKET FOR GASTROENTERITIS, BY REGION, 2021–2026 (USD MILLION)
9.3.3 MENINGOENCEPHALITIS
9.3.3.1 Severity of the disease and the need for early disease diagnosis to drive market growth
TABLE 49 MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2018–2020 (USD MILLION)
TABLE 50 MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2021–2026 (USD MILLION)
9.3.4 OTHER DISEASES
TABLE 51 MARKET FOR OTHER DISEASES, BY REGION, 2018–2020 (USD MILLION)
TABLE 52 MARKET FOR OTHER DISEASES, BY REGION, 2021–2026 (USD MILLION)
9.4 RESEARCH INSTITUTES
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTICS TESTS IN GENOMICS RESEARCH WILL DRIVE THIS MARKET SEGMENT
TABLE 53 MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018–2020 (USD MILLION)
TABLE 54 MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 55 MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION)
TABLE 56 MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)
10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 116)
10.1 INTRODUCTION
TABLE 57 MARKET, BY REGION, 2018–2020 (USD MILLION)
TABLE 58 MARKET, BY REGION, 2021–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: MARKET SNAPSHOT
TABLE 59 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing prevalence of infectious diseases—a key factor driving market growth in the US
TABLE 69 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 70 US: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 71 US: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 72 US: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 73 US: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 74 US: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 75 US: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 76 US: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Rising patient population in Canada to drive market growth in the coming years
TABLE 77 CANADA: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 78 CANADA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 79 CANADA: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 80 CANADA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 81 CANADA: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 82 CANADA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 83 CANADA: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 84 CANADA: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3 EUROPE
TABLE 85 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
TABLE 86 EUROPE: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 87 EUROPE: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 88 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 89 EUROPE: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 90 EUROPE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 91 EUROPE: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 92 EUROPE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 93 EUROPE: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 94 EUROPE: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 95 GERMANY: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 96 GERMANY: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 97 GERMANY: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 98 GERMANY: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 99 GERMANY: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 100 GERMANY: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 101 GERMANY: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 102 GERMANY: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Rising R&D expenditure in France to drive market growth
TABLE 103 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 104 FRANCE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 105 FRANCE: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 106 FRANCE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 107 FRANCE: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 108 FRANCE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 109 FRANCE: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 110 FRANCE: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.3 ITALY
10.3.3.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 111 ITALY: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 112 ITALY: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 113 ITALY: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 114 ITALY: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 115 ITALY: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 116 ITALY: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 117 ITALY: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 118 ITALY: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.4 UK
10.3.4.1 Increasing prevalence of infectious diseases to drive market growth in the UK
TABLE 119 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 120 UK: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 121 UK: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 122 UK: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 123 UK: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 124 UK: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 125 UK: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 126 UK: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 127 ROE: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 128 ROE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 129 ROE: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 130 ROE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 131 ROE: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 132 ROE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 133 ROE: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 134 ROE: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 APAC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 135 APAC: MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
TABLE 136 APAC: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 137 APAC: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 138 APAC: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 139 APAC: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 140 APAC: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 141 APAC: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 142 APAC: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 143 APAC: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 144 APAC: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
TABLE 145 CHINA: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 146 CHINA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 147 CHINA: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 148 CHINA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 149 CHINA: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 150 CHINA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 151 CHINA: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 152 CHINA: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 153 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 154 JAPAN: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 155 JAPAN: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 156 JAPAN: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 157 JAPAN: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 158 JAPAN: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 159 JAPAN: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 160 JAPAN: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 161 INDIA: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 162 INDIA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 163 INDIA: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 164 INDIA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 165 INDIA: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 166 INDIA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 167 INDIA: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 168 INDIA: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
TABLE 169 ROAPAC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 170 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 171 ROAPAC: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 172 ROAPAC: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 173 ROAPAC: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 174 ROAPAC: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 175 ROAPAC: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 176 ROAPAC: MARKET, BY END USER, 2021–2026 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 177 ROW: MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
TABLE 178 ROW: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 179 ROW: MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
TABLE 180 ROW: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 181 ROW: MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
TABLE 182 ROW: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 183 ROW: MARKET, BY END USER, 2018–2020 (USD MILLION)
TABLE 184 ROW: MARKET, BY END USER, 2021–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 176)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 185 STRATEGIES ADOPTED BY KEY POINT OF CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE MARKET (2015–2020)
11.4 MARKET SHARE ANALYSIS
TABLE 186 MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 32 MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 33 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 COMPETITIVE BENCHMARKING
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MARKET
TABLE 187 COMPANY PRODUCT FOOTPRINT
TABLE 188 COMPANY REGIONAL FOOTPRINT
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 189 KEY PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS
TABLE 190 KEY DEALS
12 COMPANY PROFILES (Page No. - 187)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES
TABLE 191 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 192 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.3 BIOMÉRIEUX SA
TABLE 193 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
12.1.4 DANAHER CORPORATION
TABLE 194 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.5 QUIDEL CORPORATION
TABLE 195 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 39 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
12.1.6 QIAGEN N.V.
TABLE 196 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.7 CO-DIAGNOSTICS, INC.
TABLE 197 CO-DIAGNOSTICS, INC.: BUSINESS OVERVIEW
FIGURE 41 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)
12.1.8 BIOCARTIS NV
TABLE 198 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 42 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
12.1.9 MERIDIAN BIOSCIENCE, INC.
TABLE 199 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
FIGURE 43 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2020)
12.1.10 THERMO FISHER SCIENTIFIC INC.
TABLE 200 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
12.2 OTHER PLAYERS
12.2.1 LUCIRA HEALTH, INC.
12.2.2 CUE HEALTH
12.2.3 OPGEN, INC.
12.2.4 BINX HEALTH, INC.
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
12.2.6 GENOMADIX
12.2.7 VISBY MEDICAL, INC.
12.2.8 QUIKPATH PTE. LTD.
12.2.9 MD-BIO
12.2.10 QUANTUMDX GROUP LTD.
12.2.11 AIDIAN OY
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 227)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the point of care molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the point of care molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global point of care molecular diagnostics market by product & service, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific and Rest of the World
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the market.
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Point of Care Molecular Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific and Rest of the World
Company profiles
- Additional ten company profiles of players operating in the point of care molecular diagnostics market
Growth opportunities and latent adjacency in Point of Care Molecular Diagnostics Market